William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital, is joined by guests Michael G. Katz, MD, FHRS, of Morristown Medical Center and Victor Nauffal, MD, of Brigham and Women`s Hospital, to discuss the treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) and how it is limited. Catheter ablation is increasingly performed, but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.

https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.063367

Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s): V. Nauffal: No relevant financial relationships with ineligible companies to disclose. M. Katz: Stocks, Publicly Traded: Medtronic PLC, Abbott Medical, Novo Nordisk, Pfizer, Inc.; Owner/Partnership/Principle: Vision Valve Technologies, LLC.